<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943446</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-018-2001</org_study_id>
    <secondary_id>2019-000886-19</secondary_id>
    <secondary_id>U1111-1225-5064</secondary_id>
    <secondary_id>NR266345</secondary_id>
    <secondary_id>NL71098.018.19</secondary_id>
    <nct_id>NCT03943446</nct_id>
  </id_info>
  <brief_title>TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of TAK-018 in reducing endoscopic&#xD;
      recurrence of intestinal inflammation in postoperative participants with CD after a planned&#xD;
      laparoscopic ileocecal resection with primary anastomosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-018. TAK-018 is used for the prevention of&#xD;
      postoperative CD recurrence. This study will evaluate the efficacy of TAK-018 in reducing&#xD;
      endoscopic recurrence of intestinal inflammation in postoperative participants with CD after&#xD;
      planned laparoscopic ileocecal resection with primary anastomosis.&#xD;
&#xD;
      The study will enroll approximately 96 participants. Participants will be randomly assigned&#xD;
      (by chance, like flipping a coin) in 1:1:1 ratio to one of the three treatment groups-which&#xD;
      will remain undisclosed to the participants and study doctor during the study (unless there&#xD;
      is an urgent medical need):&#xD;
&#xD;
        -  TAK-018 0.30 g Low dose&#xD;
&#xD;
        -  TAK-018 1.5 g High dose&#xD;
&#xD;
        -  Placebo&#xD;
&#xD;
      All participants will be asked to take the tablets twice daily immediately after a meal (that&#xD;
      is, breakfast and dinner) with water, approximately 8 to 12 hours apart.&#xD;
&#xD;
      Participants will have flexibility to either to opt for home health care (HHC) solutions at&#xD;
      Screening, Week 3, Week 6, Week 12, Week 18 and Week 30 or travel to the clinic for all&#xD;
      scheduled visits per protocol as permitted by local regulations. This flexible approach is&#xD;
      designed in response to health care delivery challenges presented by the coronavirus disease&#xD;
      (COVID-19) pandemic and to provide additional flexibility during the course of the trial.&#xD;
&#xD;
      This multi-center trial will be conducted in the United States, United Kingdom, France,&#xD;
      Austria and Germany. The overall time to participate in this study is approximately 34 weeks.&#xD;
      Participants will make final visit to the clinic or can opt for HHC visit at Week 30 (30 days&#xD;
      after the Week 26 endoscopy) for safety follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Endoscopic Recurrence of CD as Assessed by Rutgeerts Grading Scale at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Endoscopic recurrence is defined as a Rutgeerts' score greater than or equal to (&gt;=) i2. The Rutgeerts scoring is a 5-point scale used to assess endoscopic recurrence at the ileocolonic anastomosis and preanastomotic ileum. The scale ranges from i0 to i4; where i0 equal to (=) no lesions, i1= less than or equal to (&lt;=) 5 aphthous ulcers, i2= greater than (&gt;) 5 aphthous ulcers with normal mucosa between lesions or lesions are confined to the anastomosis, i3= diffuse aphthous ileitis with diffusely inflamed mucosa and i4= diffuse inflammation with larger ulcers, nodules, and/or narrowing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Fecal Calprotectin (FCP) &gt;135 Microgram per Gram (mcg/g) at Weeks 3, 6, 12, 18, 26 and 30</measure>
    <time_frame>Weeks 3, 6, 12, 18, 26 and 30</time_frame>
    <description>Stool samples will be collected for analysis of fecal calprotectin, a biomarker of intestinal inflammatory activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough: Observed Plasma Trough Concentrations of TAK-018</measure>
    <time_frame>Week 3 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>TAK-018 0.30 g Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-018 3*0.10 gram (g), tablets, orally, twice daily (BID) for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-018 1.5 g High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-018 3*0.50 g, tablets, orally, BID for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-018 placebo-matching 3*0 g tablets, orally, BID for up to 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-018</intervention_name>
    <description>TAK-018 immediate-release tablets.</description>
    <arm_group_label>TAK-018 0.30 g Low Dose</arm_group_label>
    <arm_group_label>TAK-018 1.5 g High Dose</arm_group_label>
    <other_name>EB8018</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-018 Placebo</intervention_name>
    <description>TAK-018 placebo-matching tablets.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have a documented diagnosis of CD confirmed by endoscopic biopsy before resection&#xD;
             or by tissue obtained at resection.&#xD;
&#xD;
          2. Planned to undergo a laparoscopic ileocecal resection with primary anastomosis within&#xD;
             72 hours before randomization Day 1. Confirmation that no active disease has been left&#xD;
             behind after resection will be based on surgeon's documentation in the operative&#xD;
             report.&#xD;
&#xD;
          3. With postoperative discontinuation of all concomitant medications specifically related&#xD;
             to the treatment of CD. This includes anti-tumor necrosis factor-alpha (TNF-Î±) and&#xD;
             anti-integrin therapy, anti- interleukin (IL) 12/23, thiopurines and other&#xD;
             immunomodulators, steroids, 5-minosalicylates, and prophylactic use of antibiotics for&#xD;
             the prevention of postoperative recurrence such as metronidazole.&#xD;
&#xD;
          4. Has resumed oral intake and is capable of swallowing tablets after surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has active perianal CD.&#xD;
&#xD;
          2. Has had &gt;3 previous surgical procedures for CD.&#xD;
&#xD;
          3. Has macroscopically active CD that was not resected at the time of surgery as&#xD;
             documented in the surgeon's operative report.&#xD;
&#xD;
          4. With small bowel resection that exceeds 100 centimeter (cm) or a participant who is&#xD;
             considered at risk of short bowel syndrome by the surgeon or investigator.&#xD;
&#xD;
          5. Has active or latent tuberculosis, regardless of treatment history, as evidenced by&#xD;
             any of the following: history of tuberculosis, OR positive QuantiFERON test or 2&#xD;
             successive indeterminate QuantiFERON tests, OR a tuberculin skin test reaction &gt;=10&#xD;
             millimeter (mm) (&gt;=5 mm in participants receiving the equivalent of &gt;15 milligram per&#xD;
             day (mg/day) prednisone).&#xD;
&#xD;
          6. Has chronic hepatitis B (hepatitis B surface antigen positive, or positive for both&#xD;
             hepatitis B surface antibody and hepatitis B core antibody but negative for hepatitis&#xD;
             B surface antigen) or hepatitis C infection (evident by viral replication by&#xD;
             polymerase chain reaction) within 30 days of randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>501-603-1900</phone>
      <email>sdehmel@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Stephan Dehmel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>310-652-8031</phone>
      <email>gil.melmed@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Gil Melmed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>949-557-0251</phone>
      <email>caroline.hwang@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Caroline Hwang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>720-848-2777</phone>
      <email>frank.i.scott@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Frank Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>617-638-8339</phone>
      <email>farraye.francis@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Francis Farraye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Leonard M. Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>305-243-8644</phone>
      <phone_ext>opt3</phone_ext>
      <email>mabreu1@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Maria Abreu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida/USF Health</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>813-974-2201</phone>
      <email>renee41@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Renee Marchion Beery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>404-236-2333</phone>
      <email>nkg2duke@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nitin Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>312-695-8952</phone>
      <email>emanuelle.bellaguarda@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Emanuelle Bellaguarda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>773-834-1370</phone>
      <email>asakurab@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Atsushi Sakuraba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>859-323-6423</phone>
      <email>drflom0@email.uky.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Flomenhoft</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>410-502-1559</phone>
      <email>joanna.peloquin@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Joanna Melia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>617-724-9953</phone>
      <email>aananthakrishnan@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Ashwin Ananthakrishnan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>603-650-8101</phone>
      <email>corey.a.siegel@hitchcock.org; corey.a.siegel@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Corey Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Inflammatory Bowel Disease Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>212-263-3095</phone>
      <email>jordan.axelrad@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Jordan Axelrad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>212-861-2000</phone>
      <email>james.marion@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>James Marion</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>212-305-5664</phone>
      <email>bs3270@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Bo Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>919-966-8946</phone>
      <email>hherf@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Hans Herfarth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>216-444-1711</phone>
      <email>clickb@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin Click</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>412-648-8982</phone>
      <email>biniond@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>David Binion</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Inflammatory Bowel Disease Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-1375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>615-322-0128</phone>
      <email>robin.dalal@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Robin Dalal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>713-790-3333</phone>
      <email>bpabraham@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Bincy Abraham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 512 504 23539</phone>
      <email>robert.koch@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Robert Koch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <state>Vienna</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 1 40400 62450</phone>
      <email>walter.reinisch@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Walter Reinisch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Les Hopitaux Universitaires de Strasbourg - Hopital Hautepierre</name>
      <address>
        <city>Strasbourg Cedex</city>
        <state>Alsace</state>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 3 88 12 74 41</phone>
      <email>jean-marie.reimund@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marie Reimund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Estaing</name>
      <address>
        <city>Clermont-Ferrand Cedex</city>
        <state>Auvergne</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 4 73 75 05 04</phone>
      <email>a_buisson@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Anthony Buisson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pontchaillou</name>
      <address>
        <city>Rennes Cedex 9</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 2-99-28-43-47</phone>
      <email>guillaume.bouguen@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume Bouguen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Il-de-France</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33142499597</phone>
      <email>matthieu.allez@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Matthieu Allez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Rangueil</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <state>Midi-pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 5 61 32 20 45</phone>
      <email>gilletta.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Cyrielle Gilletta de Saint Joseph</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice Hopital l'Archet</name>
      <address>
        <city>Nice Cedex 3</city>
        <state>Provence Alpes Cote D'Azur</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 4 92 03 61 68</phone>
      <email>hebuterne.x@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Hebuterne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+49 0761 270-24010</phone>
      <email>uwe.wittel@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Uwe Wittel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+49 621 3833294</phone>
      <email>wolfgang.reindl@umm.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Reindl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Luneburg</name>
      <address>
        <city>Luneburg</city>
        <state>Niedersachsen</state>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+494131772243</phone>
      <email>christian.maaser@klinikum-lueneburg.de</email>
    </contact>
    <investigator>
      <last_name>Christian Maaser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abteilung Klinische Studien</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4903419092626</phone>
      <email>ingolf.schiefke@sanktgeorg.de</email>
    </contact>
    <investigator>
      <last_name>Ingolf Schiefke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441213715879</phone>
      <email>rachel.cooney@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rachel Cooney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London North West Healthcare NHS Trust</name>
      <address>
        <city>Harrow</city>
        <state>England</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+44 2088695805</phone>
      <email>ailsa.hart@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Ailsa Hart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NWI 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+44 020 3447 7059</phone>
      <email>alex.vonroon@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Alexander von Roon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Helens and Knowsley Teaching Hospitals NHS Trust</name>
      <address>
        <city>Prescot</city>
        <state>England</state>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441514261600</phone>
      <email>rajiv.chandy@sthk.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rajiv Chandy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4401414516089</phone>
      <email>jonathan.macdonald@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jonathan MacDonald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b603b4db2bf003ab4a2e7</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

